High-dose dexamethasone (45 mg m À2 day À1 ) was used by Kolb EA et al., as improved response in ALL was observed with higher doses in a trial by Dana Farber Cancer institute. 8 We used similar dose of dexamethasone in our patients if it was tolerated.
Three patients achieved complete remission (CR), whereas eight were refractory to TVTG. All three patients who achieved response had ALL (two B-ALL and one T-ALL). The median time from achieving a CR to transplant was 48 days (range 19-65 days). Two patients (patient nos. 5 and 6), who achieved CR after TVTG, underwent allogenic stem cell transplant and were alive and free of disease after 24 and 26 months from the start of TVTG respectively. Patient no. 10, who achieved CR after TVTG, underwent allogenic stem cell transplant but subsequently died of disease relapse 13 months after treatment of TVTG. One patient died of serious uncontrolled infection of multiresistant Stenothrophomonas maltophilia pneumonia, while on TVTG. Six patients had disease refractory to TVTG. Patient no. 11, who had received TVTG for T-ALL, continued to have stable disease and was alive after 79 days of receiving TVTG without receiving any further treatment.
The major toxicity was myelosuppression including grade 4 neutropaenia and thrombocytopaenia (11 patients) and grade 3 anaemia (nine patients). The median duration of neutropaenia was 19 days. The most common grade 3 or 4 non-haematological toxicity was diarrhoea (n ¼ 5). Six patients required ITU admission of which, one died of severe uncontrolled infection with multiresistant S. maltophilia pneumonia. Three patients had grade 4 septic shock, two each had grade 4 mucositis, grade 4 pneumonia, grade 4 bowel toxicity and one had grade 3 liver toxicity.
In summary, three (37%) out of eight patients with ALL achieved CR and underwent allogenic stem cell transplant. All three patients who achieved remission were young (16, 25, 36 years). Since, heavily pretreated multiply relapsed or refractory ALL patients do not have better therapeutic options, TVTG may be considered in such young adults with good performance status. High mortality rate (9%) and toxicity profile should be taken into account while treating adults with TVTG. Further studies would be required to define the role of TVTG in other advanced haematological malignancies. Heparan sulphate is a key structural component of the extracellular matrix (ECM) that contributes to the self-assembly and integrity of the matrix by binding structural proteins including collagen, laminin and fibronectin. The endoglycosidase enzyme, heparanase, participates in the degradation and remodelling of the ECM by cleaving heparan sulphate molecules to yield bioactive fragments that modulate growth factor activity. Heparanase activity also induces an angiogenic response by releasing angiogenic factors sequestered by heparan sulphate in the ECM. In contrast to the various enzymes that degrade protein components of the ECM, a single mammalian heparanase appears to be responsible for degrading heparan sulphate. As such, expression of heparanase activity is associated with a range of normal and pathological processes that involve degradation and remodelling of the ECM including wound healing, inflammation, neovascularization and tumour metastasis. 1 Expression of heparanase in normal tissues is restricted to a few cell types including endothelial cells, keratinocytes and placental trophoblasts. In the haematopoietic system, heparanase is expressed in platelets, neutrophils, macrophages and activated lymphocytes, where it mediates extravasation during inflammatory and immune responses. 2 In contrast to normal tissues, heparanase is widely expressed in primary human tumours where high levels of expression are correlated with increased local and distant metastasis, increased tumour Letters to the Editor vascularization and reduced post-operative survival in cancer patients. 1, 3 In animal models, overexpression of heparanase confers accelerated tumour growth and an invasive phenotype. 1 Conversely, heparanase gene silencing is associated with a marked inhibition of tumour progression. 4 Expression of heparanase has been detected in blasts of human leukaemias, including acute myeloid leukaemia and acute lymphoblastic leukaemia (ALL); however, its involvement in haematological malignancies has not been systematically assessed. 5, 6 Ostrovsky et al. 7 have recently shown that a single-nucleotide polymorphism (SNP) of the heparanase gene (rs11099592), which causes the substitution of arginine with lysine at position 307 (Arg307Lys) of the heparanase polypeptide, was significantly associated with ALL. They reported that genotype and allele frequencies of the SNP in a group of 43 Israeli ALL patients were significantly different from a group of 103 healthy control individuals ( w 2
, and a haplotype of three heparanase SNPs (rs4693608; rs11099592; rs4364254) was identified that was associated with reduced heparanase expression in control individuals. The authors concluded that heparanase gene SNPs may influence basal expression of the gene and that the Arg307Lys SNP is an important determinant in the pathogenesis of ALL. 7 We sought to confirm the association of the Arg307Lys SNP with ALL reported by Ostrovsky et al. 7 by comparing the genotype and allele frequencies of the SNP in a population of Northern Irish ALL patients with a group of healthy control individuals. We speculated that it would be of interest to determine if the findings reported for the Israeli population extended to other, less heterogeneous ethnic groups such as the Northern Irish.
Genotype and allele frequencies for the Arg307Lys SNP were compared in a group of 58 Northern Irish ALL patients (32 male patients, 26 female patients; age: 2-70 years) and 45 healthy control individuals (23 male subjects, 22 female subjects; age: 2-65 years). A 273 bp fragment of the heparanase gene spanning the site of the rs11099592 SNP was amplified by PCR. Digestion of the PCR product with the BstNI restriction enzyme yielded diagnostic bands of 192 bp indicating the Arg allele and 257 bp indicating the Lys allele. 7 In contrast to the findings of Ostrovsky et al., 7 a comparison of genotype and allele frequencies for the Arg307Lys SNP showed no significant differences between the Northern Irish ALL patients and the healthy control group ( w 7 revealed substantial differences in the genotype and allele frequencies for the Northern Irish and Israeli ALL and control populations ( Table 1) .
The lack of concordance between genotype and allele frequencies in the Northern Irish and Israeli populations may suggest ethnic variation in the frequency of Arg307Lys SNP. The Israeli population studied by Ostrovsky et al. 7 included individuals from a number of ethnic groups including Ashkenazi, North African, Mediterranean and Near Eastern Jewish populations. In a previous study by the same group, significant differences between these populations in the genotype and allele frequencies of several heparanase SNPs were identified, although these did not include the Arg307Lys SNP. 8 It is of interest to note, however, that the allele frequencies for the Arg307Lys SNP reported by Ostrovsky et al. 8 in this earlier study are strikingly different from those reported in their subsequent study 7 and bear a close similarity to our data on the Northern Irish population ( Table 2) .
All of the patients and control individuals included in our study were of Northern Irish origin. Due to its geographical isolation and historically low levels of inward migration, the Irish population may be considered to be genetically more homogeneous relative to other populations, including the Israeli population studied by Ostrovsky et al. 7 As such, the influence of genetic factors predisposing to complex conditions such as ALL may be more apparent in our population. In conclusion, our findings on Northern Irish ALL patients have failed to confirm the association between the heparanase Arg307Lys SNP and ALL previously reported for the Israeli population. This may be related to the heterogeneous nature of the Israeli population studied by Ostrovsky et al. 7 Further studies may provide 1 observed higher G allele frequency (83.63%) in North Irish ALL patients compared with their normal individuals (55.56%), whereas in our investigation, 2 we found the prevalence of allele A in Israeli ALL patients (27.91%) compared with Israeli healthy individuals (16.51%). This A allele prevalence was also confirmed by the following haplotype analysis performed for five SNPs (rs4693608, rs11099592, rs4364254, rs6856901, rs4693602) in the HPSE gene.
We may suggest that the absence of consensus in the two reports may be the results of the differences between the two studied populations. For example, many studies reveal no correlation between C3435T multidrug-resistance gene 1 (MDR1) polymorphism and MDR1 expression, especially between Caucasians and Japanese. 3, 4 It is possible that certain haplotypes are more prevalent in one population than another. It is clear that only a large study with precise determination of subgroups and with appropriate control individuals may allow in the future to clarify the role of heparanase gene in ALL development. In addition, only future studies will detect the role of HPSE gene SNPs (as functional polymorphisms or as a marker) in expression and function of heparanase, and their involvement in various pathological processes.
In their letter, Winter et al. 1 tried to combine our two studies that were based on different samples. The aim of our first study was to characterize the HPSE gene SNPs in four Jewish populations and to compare them to non-Jewish populations. 5 The ethnic origin of each individual was established by the origin of both maternal and paternal grandparents. In our second study, 2 we investigated the association of HPSE gene SNPs with hematological malignancies. In this study, our patients group was heterogeneous, representing various Israeli ethnic populations (not only Ashkenazi, North Africans, Mediterranean and Near Eastern Jews, but also Yemenite, Ethiopian and other Jews and non-Jewish individuals). For this reason, we chose our 103 control individuals, randomly from the same Israeli population. Thus, the attempt of Winter and co-workers to compare these two different studies leads to incorrect conclusions.
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